PURPOSE The preservative benzalkonium chloride (BAK) may adversely affect ocular surface health. This study evaluated symptoms of ocular surface disease (OSD) in patients previously treated with a BAK-preserved therapy to lower their intraocular pressure, who either continued that therapy or switched to a BAK-free therapy. METHODS Eligible adult patients with ocular hypertension or open-angle...

Aim: To investigate the effects of a non-steroidal anti-inflammatory drug (NSAID) ophthalmic solution on latanoprost induced intraocular pressure (IOP) reduction using normal volunteers. Methods: This study was conducted as a prospective and observer masked clinical trial. 13 normal volunteers were enrolled. After measurement of basal IOP and ophthalmic examination, latanoprost ophthalmic solut...

We compared the ocular hypotensive effect for 24 hours and the tolerability of latanoprost stored at 4 degrees C and 30 degrees C. Seventeen healthy volunteers were included in this crossover trial. Latanoprost 0.005% (Xalatan) was stored at 4 degrees C or 30 degrees C for 4 weeks in the dark. The subjects enrolled to the study were randomly assigned to receive either latanoprost stored at 4 de...

PURPOSE This study contrasts the utilization of adjunctive medication associated with travoprost, bimatoprost, or latanoprost, as primary glaucoma therapies. METHODS Patients in the Medco Health database who initiated prostaglandin analog therapy on travoprost, bimatoprost or latanoprost between January 1, 2002 and July 31, 2002 were selected if they had no prostaglandin analog use in the pri...

BACKGROUND Several studies have investigated the effect of latanoprost on intraocular pressure (IOP). We compared the IOP-lowering effects of three higher concentrations of latanoprost with the commercially available concentration of 0.005% (50 μg/mL) in patients with primary open-angle glaucoma or ocular hypertension. METHODS Treatment-naive subjects or those receiving IOP-lowering medicatio...

Aims: To study the effect of axial length on the hypotensive effect of latanoprost in primary open angle glaucoma (POAG) in a prospective, observational study. Methods: The authors measured axial length and baseline intraocular pressure (IOP) of 109 eyes with POAG, and then repeated the IOP measurements at 1, 3, and 6 months after starting treatment with latanoprost. Results: The mean IOP level...

The fixed-combination preparation of timolol and latanoprost has been available in Europe since 2001. Evidence supporting its level of clinical efficacy has been slowly accumulating, with some studies suggesting clear benefit and others showing only a modest additional effect relative to its individual components. Studies demonstrating long-term protection of visual function are sparse and more...

AIMS To study the effect of axial length on the hypotensive effect of latanoprost in primary open angle glaucoma (POAG) in a prospective, observational study. METHODS The authors measured axial length and baseline intraocular pressure (IOP) of 109 eyes with POAG, and then repeated the IOP measurements at 1, 3, and 6 months after starting treatment with latanoprost. RESULTS The mean IOP leve...

INTRODUCTION To report the effect of topical latanoprost on the position of a subluxated lens. CASE PRESENTATION After 0.005% latanoprost was administered topically to a patient with ocular hypertension due to a pseudoexfoliation syndrome and a subluxated lens, the position of the lens was examined by slit-lamp biomicroscopy, and the ciliary body thickness by ultrasound biomicroscopy. The len...

PURPOSE To evaluate the effect of latanoprost on central corneal thickness (CCT) in patients with unilateral normal-tension glaucoma (NTG). METHODS A total of 38 patients, with unilateral NTG, who were being treated in our glaucoma clinic and were receiving 0.005% latanoprost monotherapy over 24 months, were included in this study. The data were collected, retrospectively, with reviewing of t...